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Abstract
γ-Secretase is a membrane-embedded protease complex, with presenilin as the catalytic 
component containing two transmembrane aspartates in the active site. With more than 90 known 
substrates, the γ-secretase complex is considered “the proteasome of the membrane”, with central 
roles in biology and medicine. The protease carries out hydrolysis within the lipid bilayer to cleave 
the transmembrane domain of the substrate multiple times before releasing secreted products. For 
many years, elucidation of γ-secretase structure and function largely relied on small-molecule 
probes and mutagenesis. Recently, however, advances in cryo-electron microscopy have led to the 
first detailed structures of the protease complex. Two new reports of structures of γ-secretase 
bound to membrane protein substrates provide great insight into the nature of substrate recognition 
and how Alzheimer’s disease-causing mutations in presenilin might alter substrate binding and 
processing. These new structures offer a powerful platform for elucidating enzyme mechanisms, 
deciphering effects of disease-causing mutations, and advancing Alzheimer’s disease drug 
discovery.
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The γ-secretase complex is a founding member of a family of intramembrane-cleaving 
proteases (I-CLiPs) that carry out hydrolysis of substrates within the hydrophobic 
environment of the lipid bilayer.1 These proteases contain membrane-embedded active sites 
that converged evolutionarily on the same basic mechanisms found in soluble proteases and 
include site 2 protease (S2P) metalloproteases, presenilin-type aspartyl proteases, and the 
rhomboid serine proteases.2 Found in virtually all forms of life, I-CLiPs cut within the 
transmembrane domain (TMD) of their substrates and play a broad range of critical roles in 
biology.3–6
γ-Secretase was initially defined as an activity that cleaved the TMD of the amyloid 
precursor protein (APP) to produce the amyloid β-peptide (Aβ) that is deposited as cerebral 
plaques in Alzheimer’s disease.7 Missense mutations in the small Aβ region of APP cause 
familial Alzheimer’s disease (FAD), altering the production or properties of Aβ to 
strengthen its tendency to aggregate.8,9 In 1995, other FAD missense mutations were found 
in presenilin-1 and −2 (PSEN1 and PSEN2, respectively),10,11 multipass membrane proteins 
that were then only known to be distantly related to an obscure gene in the roundworm 
Caenorhabditis elegans involved in spermatogenesis.12
Presenilin FAD mutations were soon found to alter Aβ production at the level of γ-
secretase,13–18 and knockout of PSEN1 dramatically reduced the level of Aβ formation by 
γ-secretase.19,20 Meanwhile, pharmacological evidence suggested that γ-secretase is an 
aspartyl protease.21 Together, these observations led to the discovery of two completely 
conserved TMD aspartates in presenilin that are essential for γ-secretase activity22 and the 
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identification of presenilin as the target of inhibitors of γ-secretase directed to its active site.
23,24 Thus, presenilin was identified as a novel membrane-embedded protease, an aspartyl I-
CLiP.
Concurrently, genetic studies in C. elegans and mice connected presenilins to the Notch 
family of cell-surface receptors.25–27 Signaling from Notch is essential for the determination 
of cell fate in embryogenesis in all metazoans,28 and knockout of presenilins leads to 
embryonic-lethal phenotypes similar to that seen upon knockout of Notch1.26,27 Signaling 
from Notch1 was found to be dependent on the release of its intracellular domain through 
cleavage within the TMD of the receptor.29 These findings converged with those for APP 
proteolysis, leading to the discovery that the presenilin-dependent γ-secretase is the same 
protease that cleaves Notch and that γ-secretase is an essential component of the Notch 
signaling pathway.30,31
Follow-up reports quickly confirmed that the two conserved TMD aspartates in presenilin 
are essential for its endoproteolysis to the N-terminal fragment (NTF) and C-terminal 
fragment (CTF) and for γ-secretase activity.32–34 Nevertheless, lingering doubts about the 
proteolytic function of presenilin remained, because the protein could not be demonstrated 
to have this activity on its own. These concerns were partially allayed by the discovery of 
another polytopic membrane protein as an aspartyl protease, bacterial type 4 prepilin 
peptidase (TFPP).35 Although TFPPs have catalytic aspartates outside of the membrane and 
are evolutionarily unrelated to presenilins, they do share a GxGD motif containing one of the 
catalytic aspartates.36 This motif is important not only for protease activity but also for 
substrate selectivity in presenilins (e.g., Notch vs APP).36 Complete acceptance of presenilin 
as a protease came with the discovery of a family of presenilin homologues with catalytic 
activity on their own, exemplified by signal peptide peptidase.37,38
Although presenilin was identified as the catalytic component of γ-secretase, evidence 
clearly pointed to presenilin being part of a larger complex. Presenilin alone did not show γ-
secretase activity, and presenilin expressed in the endoplasmic reticulum (ER) is cleaved into 
a tightly regulated and metabolically stable NTF and CTF in the Golgi apparatus before 
moving further along the secretory pathway and to the cell surface.39–43 Moreover, 
presenilin NTFs and CTFs remain associated and enter into a high-molecular weight 
complex.43–46 Ultimately, through extensive genetic and biochemical investigations, three 
other membrane protein components were identified: nicastrin,47 anterior pharynx-defective 
1 (Aph-1),48–50 and presenilin enhancer 2 (Pen-2)51,52 (Figure 1). Expression of these three 
proteins along with presenilin reconstituted γ-secretase activity in mammalian cells53,54 and 
yeast,55 and all four proteins, with presenilin as NTF and CTF, co-purified using an 
immobilized activity-based probe.54
The γ-secretase complex is now known to process more than 90 different type I integral 
membrane proteins after sheddase-mediated removal of their ectodomains.56–58 Although in 
a few cases the release of substrate intracellular domain leads to cell signaling analogous to 
that of Notch,59,60 cleavage of most substrates by γ-secretase is thought to be a means of 
clearing these protein stubs from the membrane. For this reason, γ-secretase has been 
dubbed “the proteasome of the membrane”.61 Moreover, substrate processing by γ-secretase 
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is now known to be quite complicated, with an initial cut occurring in the substrate TMD 
near the membrane–cytosol interface followed by C-terminal trimming of the membrane-
bound product to smaller secreted peptides.
Processing of APP is the most studied. An initial endoproteolytic cut leads to the formation 
of a 48-or 49-residue Aβ peptide (Aβ48 or Aβ49, respectively) and corresponding APP 
intracellular domain (AICD) fragments.62–66 Aβ48 or Aβ49 is then processed through a 
carboxypeptidase activity of γ-secretase,67,68 trimming generally every three amino acids.
69–71 Thus, the production of Aβ occurs along two pathways: Aβ49 → Aβ46 → Aβ43 → 
Aβ40 and Aβ48 → Aβ45 → Aβ42 → Aβ38 (Figure 2). Interestingly, presenilin 
endoproteolysis also involves processive tripeptide trimming,72 and Notch1 is likely 
processed similarly by γ-secretase.73 As the γ-secretase complex contains only one of each 
component,74 the protease has only one active site that is apparently responsible for all of 
these substrate TMD processing events.
STRUCTURE AND FUNCTION: MOLECULAR PROBES AND MUTAGENESIS
Early studies of γ-secretase structure and function relied largely on peptidomimetic 
inhibitors and mutagenesis of substrates or the enzyme. The first designed inhibitors were 
substrate-based transition-state analogue (TSA) inhibitors, difluoroketone peptidomimetics 
based on the APP TMD.21,75 Hydration of the difluoroketone results in a geminal diol that 
closely resembles an intermediate formed in aspartyl protease catalysis when water attacks 
the carbonyl carbon of the scissile amide bond.76 These and related peptidomimetic TSA 
inhibitors suggested that γ-secretase is an aspartyl protease.21 This finding, along with the 
requirement of presenilin for γ-secretase processing of APP in cells,19 led to the discovery 
of presenilin as the catalytic component of the enzyme through mutagenesis of two 
conserved TMD aspartates.22 These aspartates were also found to be absolutely required for 
the processing of presenilin into NTF and CTF, suggesting that presenilin is a zymogen that 
undergoes autoproteolysis.22 Identification of the other components of the enzyme 
demonstrated that this autoproteolysis is triggered only after assembly of all four members 
into the complex.53–55
Variations of these early peptidomimetic TSA inhibitors were used as probes for substrate 
binding pockets in the enzyme active site. The protease was found to have relatively loose 
specificity,21 a finding consistent with the later discovery of many other TMD substrates 
with little or no sequence conservation.56–58 TSA probes also suggested large pockets –S1, 
S1′, and S3′–in the active site that accommodate substrate residues P1, P1′, and P3′, while 
the S2′ pocket is smaller.77,78 Moreover, TSA residues P1′, P2′, and P3′ were essential for 
inhibitory potency, but adding a P4′ residue had essentially no effect on potency.78 Thus, 
the enzyme apparently has only three corresponding S′ pockets, a feature later revealed to 
be an important determinant of the carboxypeptidase trimming activity of γ-secretase.79 
TSA inhibitors were also converted into affinity labeling reagents that were covalently 
attached to presenilin NTF and CTF.23,24 These observations suggested that the active site 
was at the interface between these two presenilin subunits, consistent with the fact that NTF 
and CTF each contain one of the conserved aspartates essential for γ-secretase activity.
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Other types of substrate-based probe that helped understand γ-secretase structure and 
function are helical peptide inhibitors (HPIs). A series of peptides based on the APP TMD 
were designed, installing the helix-inducing α-aminoisobutyric acid (Aib) residue.80 Certain 
APP TMD residues were swapped with Aibs, spacing them apart so that Aib residues would 
array along one face of the helix, presenting APP residues along the rest of the TMD for 
interaction with the protease. The idea was to mimic the helical conformation of the APP 
TMD as it would be upon initial interaction with γ-secretase. The designed HPIs could be 
remarkably potent inhibitors of γ-secretase activity, both in cells and in isolated enzyme 
assays.80,81 Conversion of potent HPIs to affinity labeling reagents led to covalent binding to 
presenilin NTF and CTF,82 as seen with TSA probes. However, TSA inhibitors could not 
compete with 10-residue HPI affinity probes, and 10-residue HPIs could not compete with 
TSA affinity probes, indicating different binding sites for the two types of probes. The 
labeling of PSEN1 NTF and CTF by HPI and TSA probes is consistent with a recent tour de 
force report of systematic mutagenesis of the recombinant APP substrate with an unnatural 
photo-cross-linkable amino acid.83 Very little cross-linking to other γ-secretase components 
was observed. Intriguingly, repeating these experiments with two different FAD mutant 
PSEN1-containing γ-secretase complexes resulted in altered patterns of photolabeling to 
PSEN1 NTF and CTF, suggesting that these disease-causing mutations alter the positioning 
of the substrate for proteolysis.
The findings with HPI-and TSA-based affinity probes were consistent with the observation 
that the endogenous APP substrate could be co-purified with γ-secretase using an 
immobilized TSA inhibitor,84 demonstrating that the substrate could bind to the protease 
even when the active site was occupied by an inhibitor. This co-purification suggested the 
existence of an initial substrate docking site distinct from the active site, part of a lateral 
gating mechanism for entry of the substrate into the active site. The water-containing active 
site was expected to be inside presenilin, sequestered from the hydrophobic environment of 
the lipid bilayer, with substrate TMD first interacting with presenilin on its lipid-exposed 
surface. The 10-residue HPI probes apparently bind to this docking exosite. Interestingly, 
potent 13-residue HPI probes could compete with both 10-residue HPI and TSA,82 
suggesting that the docking site and active sites are proximal, within the distance spanned by 
three amino acids.
The finding that mimics of the APP TMD in a helical conformation could bind tightly to the 
enzyme was also consistent with an earlier phenylalanine scanning mutagenesis experiment 
of the APP TMD in transfected cells.85 Systematic Phe mutation in the APP TMD resulted 
in effects on the major secreted Aβ peptides (Aβ40 and Aβ42), with changes in the Aβ42/
Aβ40 ratio that followed a repeating pattern every three or four residues (approximately the 
turn of an α-helix). However, this Phe scanning approach was revisited recently,79 with the 
understanding of the carboxypeptidase activity and two pathways by which Aβ40 and Aβ42 
are produced (see Figure 2). The new Phe scanning study was also undertaken with the 
information gained from TSA inhibitor probes that the S2′ pocket is smaller than S1, S1′, 
and S3′ and cannot accommodate a Phe residue.78 Phe mutation affected the Aβ42/Aβ40 
ratio in a manner completely predictable with processive proteolysis along the two pathways 
and with cleavage blocked wherever Phe is in the P2′ position in the APP TMD. Moreover, 
placing Phe in both positions 50 and 51 (Aβ numbering) virtually blocked ε cleavage and all 
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Aβ production, but the mutant substrate could nevertheless co-immunoprecipitate with the 
γ-secretase complex. Taken together, the results suggest a model in which substrate TMD 
interacts as an α-helix with the enzyme before unwinding in part into the active site and 
filling pockets S1′–S3′. After ε cleavage, this unwinding is repeated, with trimming 
generally every three amino acids dictated by these three pockets (Figure 3). The stability of 
the interaction between longer Aβ peptide intermediates and the protease likely determines 
the likelihood of C-terminal trimming versus release as products, and FAD mutations can 
apparently decrease the affinity of the enzyme for Aβ intermediates.86,87
Cysteine mutagenesis in PSEN1 coupled with cross-linking via disulfide bond formation has 
also proven to be a valuable approach to deciphering the structure and function of presenilin 
within the active γ-secretase complex. PSEN1 contains five native cysteine residues, and all 
of these can be replaced with serine to form a cysteine-less PSEN1 that retains the ability to 
assemble into an active γ-secretase complex.88,89 Partial replacement of native cysteines 
along with oxidation with copper and 1,10-phenanthroline led to the finding that Cys92 in 
TMD1 could cross-link to either Cys410 or Cys419 in TMD8, observed as cross-linking of 
PSEN1 NTF and CTF by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE).90 Thus, TMD1 and TMD8 in PSEN1 are apparently directly adjacent, a finding later 
borne out by cryo-electron microscopy (cryo-EM) structure determination.91 Cysteine 
mutagenesis of the catalytic aspartates in TMD6 and TMD7 in an otherwise cysteine-less 
PSEN1 results in assembly with other complex members, but this mutant PSEN1 is unable 
to undergo autoproteolysis and is completely inactive.89 Nevertheless, oxidative conditions 
led to the shifting of the PSEN1 holoprotein by SDS–PAGE, suggesting that the two 
cysteines replacing the catalytic aspartates are immediately proximal as expected.
Systematic replacement of PSEN1 residues with Cys in the otherwise Cys-less mutant was 
also coupled with use of biotinylated thiol-containing probes, an approach called the 
substituted cysteine accessibility method (SCAM).92 Using SCAM, the water accessibility 
of specific residues could be determined. Cross-linking using whole cells could identify 
water-accessible residues on the extracellular side, while cross-linking using 
proteoliposomes could also reveal water-accessible residues on the intracellular side. In this 
way, TMD6 and TMD7 were found to be exposed to a hydrophilic environment, with the 
two catalytic aspartates more limited in their water accessibility,88,89 findings confirmed by 
the first detailed cryo-EM structures of γ-secretase. The SCAM method could also identify 
key residues not initially observed by cryo-EM. A portion of hydrophilic loop 1 (L1) was 
labeled with a pattern consistent with a short α-helical conformation, and this region was 
thought to be involved in substrate recognition.93 These findings were recently confirmed 
upon cryo-EM elucidation of substrate-bound γ-secretase.94,95 Double Cys labeling and use 
of cross-linking reagents could additionally reveal proximal residues in NTF and CTF (i.e., 
by generating PSEN1 NTF/CTF that co-migrated with holoprotein).96 SCAM labeling could 
also be conducted in the presence of small-molecule γ-secretase inhibitors and modulators. 
Blocking of specific SCAM labeling sites thereby suggested sites of compound binding. In 
this way, the binding of HPI and TSA probes to distinct sites was confirmed and tentatively 
identified residues involved in the docking site and active site.97
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Aside from SCAM analysis of PSEN1, the presenilins have been extensively mutated in 
attempts to understand structure and function. While a full review of these studies is beyond 
the scope of this Perspective, three critical motifs in PSEN1 identified through mutagenesis 
are worth mentioning here: the GxGD motif, discussed previously as being critical for 
proteolytic function and substrate selectivity,36,98–100 a PAL motif located in TMD9, and the 
hydrophilic loop 1 (L1)/TMD2 region. The PAL motif is essential for PSEN1 
endoproteolysis and γ-secretase activity. Nonconservative mutations lead to complete loss of 
proteolytic function101 and alter the binding of active site-directed TSA probes.102 These 
findings were later confirmed by cryo-EM elucidation of the γ-secretase structure, revealing 
that the PAL motif is part of the active site.91 Mutagenesis of L1/TMD2 of PSEN1 
suggested that this region is critical for PSEN1 autoproteolysis and coordination between the 
substrate docking site and the catalytic core.103 This notion is likewise supported by recent 
cryo-EM structures of γ-secretase bound to substrates.94,95
While small-molecule probes and mutagenesis helped to improve our understanding of the 
structure and function of presenilin in γ-secretase, other approaches were required to begin 
elucidating how the subunits of the protease complex interact with each other. Partial 
dissociation of the isolated complex using the detergent dodecyl D-maltoside revealed that 
PSEN1 NTF interacts with Pen-2 and nicastrin interacts with Aph-1.104 The PSEN1 CTF 
was found in two other partial complexes, one with PSEN1 NTF and Pen-2 and the other 
with Aph-1 and nicastrin. These findings of subunit interactions were confirmed using cross-
linking reagents105 and were consistent with evidence that the apparent order of assembly of 
the complex involves nicastrin and Aph-1 interaction,49 then addition of PSEN1 holoprotein 
to form a tripartite complex,53,106,107 and finally addition of Pen-2, which triggers PSEN1 
autoproteolysis53 (Figure 4). TMD swapping experiments with PSEN1 identified TMD4 as 
being essential for interaction with Pen-2, and more focused mutagenesis revealed a YNF 
motif in TMD4 as being specifically critical.108,109 All of these interactions were later 
confirmed by the cryo-EM structures of γ-secretase. This confirmation works both ways. 
Cryo-EM reconstructions should be consistent with results from biochemical experiments to 
mitigate concerns about the validity of the cryo-EM model.
Biochemical experiments also helped to improve our understanding of the role of nicastrin in 
substrate recognition by the γ-secretase complex. The nicastrin ectodomain was found to 
have a sequence similar to those of certain aminopeptidases,110 although all conserved 
catalytic residues are not present (i.e., nicastrin does not have aminopeptidase activity111). 
Co-immunoprecipitation of Notch and APP substrates of γ-secretase with the nicastrin 
ectodomain led to the suggestion that nicastrin interacts with the N-terminus of γ-secretase 
substrates, thereby guiding the substrate to the active site on presenilin.112 However, these 
findings were inconsistent with other studies,113 the most notable being a recent report114 
revealing that (1) peptides based on the N-terminus of substrate do not inhibit substrate 
processing, (2) mutagenesis of the N-terminal residue of substrate has no effect on the 
kinetics of substrate processing, and (3) acetylation of the substrate N-terminus also did not 
affect the substrate processing rate. Instead, the length of the extracellular ectodomain of the 
substrate was found to be the critical factor. Longer substrates are cleaved more poorly,
114–116 and only the substrate TMD is required for high-affinity binding and processing by 
γ-secretase.114 These observations suggested that the nicastrin ectodomain functions as a 
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gatekeeper for substrates, sterically blocking the approach of substrates with ectodomains 
that are too long.114 Consistent with this model, reduction of the disulfide bonds in nicastrin 
resulted in conformational changes (i.e., partial unfolding) and increased access of longer 
substrates for processing by γ-secretase. This topic will be revisited later in light of detailed 
cryo-EM structure determination of the protease complex.
STRUCTURE AND FUNCTION: CRYO-EM IMAGES
Recent advances in cryo-EM–particularly the development of direct electron detection in 
combination with computational single-particle analysis, image sorting, and three-
dimensional (3D) reconstruction–have revolutionized structural biology, providing atomic-
resolution structures of previously inaccessible protein complexes.117 The size, complexity, 
hydrophobicity, and heterogeneous glycosylation of γ-secretase make it highly challenging 
to crystallize for X-ray diffraction. Other I-CLiP family members have proven to be 
amenable to crystallography,118–121 but the rhomboid serine proteases, the S2P 
metalloproteases, and the presenilin homologue aspartyl proteases are much smaller and 
single polypeptides, with chemically and thermally stable orthologs found in the microbial 
world. The crystal structure of an archaeal presenilin homologue confirmed the nine-TMD 
topology of PSEN1 and showed the two catalytic aspartates in TMD6 and TMD7 adjacent to 
each other.121 However, these aspartates were not close enough or oriented properly to 
coordinate with and activate a water molecule for use in hydrolysis.
The first reported cryo-EM images of the γ-secretase complex provided poor resolution, 
ranging from 12 to 48 Å.122–125 Although rather amorphous, these 3D reconstructions 
provided rough dimensions of the complex, suggested the location of the nicastrin 
ectodomain and a membrane-embedded hydrophobic belt, and indicated the presence of 
cavities for entry of water into the active site. Subsequent structures suggested flexibility in 
the nicastrin ectodomain, with three conformational states captured, and a more compact 
structure of the complex in the presence of inhibitors.126,127 Nevertheless, the inability to 
resolve amino acids or even TMDs severely limited a more specific understanding of 
structure and function.
In 2014, the first detailed structure of the γ-secretase complex, determined by cryo-EM 
single-particle analysis with 4.5 Å overall resolution, was reported from the laboratories of 
Y. Shi at Tsinghua University in Beijing and S. Scheres at the MRC Laboratory of Molecular 
Biology in Cambridge, U.K.128 In addition to the advances in cryo-EM technology, the 
ability to express large quantities of the complex proved to be critical. The development of a 
tetracistronic construct allowed expression of all four components of γ-secretase in roughly 
equal levels upon transient transfection into human embryonic kidney (HEK) 293 cells in a 
suspension culture. This first detailed structure of the protease complex revealed the TMDs 
in a horseshoe-shaped arrangement. A lack of side-chain features for the TMDs prevented 
assignment of the four γ-secretase subunits. However, the crystal structure of an archaeal 
presenilin homologue121 led to a speculative assignment for PSEN1 and tentative location of 
the active site on the concave side of the horseshoe-shaped TMD arrangement. Hovering 
over the active site was the aminopeptidase-like domain of nicastrin, seemingly positioned 
perfectly to interact with the substrate N-terminus and guide substrate TMD into the active 
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site. Crystallization of a microbial eukaryotic nicastrin homologue129 validated the 3D 
reconstruction of this subunit within the γ-secretase complex as elucidated by cryo-EM, and 
indeed, the ectodomain is structurally similar to a large family of peptidases.
The following year, however, a new report emerged from the Shi–Scheres collaboration of 
γ-secretase at 3.4 Å overall resolution, with clear assignment of the TMDs.91 The revised 
structure revealed that the active site actually resides on the convex side of the horseshoe-
shaped TMD arrangement (Figure 5). The new arrangement had immediate implications for 
the role of nicastrin, validating a concurrent report (mentioned earlier here) that nicastrin 
serves as a gatekeeper to sterically block potential substrates with long extracellular 
ectodomains from approaching the active site114 (Figure 6). The aminopeptidase-like 
domain of nicastrin was now positioned on the opposite side from approaching the substrate, 
in a way that would require extreme conformational contortions to bind the substrate N-
terminus in a productive manner.
The new structure, now correctly identifying presenilin-1 and its TMDs, was also much 
more consistent with the previously reported crystal structure of an archaeal presenilin 
homologue.121 Interestingly, TMD2 of PSEN1 was poorly resolved, implying a mobility that 
suggested that this TMD could function as the gate for the lateral approach of substrate into 
the active site. Nevertheless, an atomic model for this TMD was generated on the basis of 
the crystal structure of the archaeal presenilin homologue. In both cases, the catalytic 
PSEN1 aspartates in TMD6 and TMD7 were positioned ∼10 Å apart (from Cα to Cα), 
relatively close but farther away than in active aspartyl proteases. Meanwhile, the PAL motif 
in PSEN1 TMD9 was proximal to these aspartates and appears to be part of the active site, 
as had been previously suggested.101,102 These observations led to the speculation that 
substrate binding initiates conformational changes that bring the aspartates closer, allowing 
them to coordinate with water and activate it for proteolysis.
The arrangement of the subunits within the complex was consistent with previous 
biochemical studies104,105 and revealed further details. The single nicastrin TMD interacts 
with TMD1, TMD5, and TMD7 of Aph-1, while TMD2 and TMD4 of Aph-1 associate with 
TMD8 and TMD9 of PSEN1 (as the CTF subunit). The three most C-terminal residues of 
the PSEN1 CTF (FYI) are inserted into a hydrophobic pocket in Aph-1 on the extracellular 
side. The Pen-2 topology was revealed as three TMDs, with two of these being short and 
together dipping in and out of the predicted boundary of the membrane on the intracellular 
side. Pen-2 was bound to TMD4 of the PSEN1 NTF, specifically to a YN motif, as 
suggested from mutagenesis experiments.108,109
The Scheres–Shi collaboration further developed their cryo-EM single-particle analysis of 
γ-secretase, using image classification along with masked refinement to focus on 
conformationally flexible parts of the protease complex, PSEN1 in particular.130 In this way, 
three different classes of enzyme conformation were identified, with an overall resolution of 
3.5 Å. Major differences were seen among the three classes, particularly with respect to 
PSEN1 TMD2 and TMD6. TMD2 was visible in only class 1 (Figure 7A), while TMD6 
adopted a different conformation in all three classes. An unidentified rod-shaped density was 
observed in class 1 and class 2, filling in a cavity created by PSEN1 TMD2, TMD3, and 
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TMD5. Side chains of this rod-shaped density could not be observed, but the peptide 
backbone adopted a clear helical conformation, becoming random coiled and then invisible 
as it approached the catalytic aspartates. This peptide was suggested to be a composite of 
various γ-secretase substrates that each co-purified with separate enzyme complexes. The 
conformational flexibility of TMD2 again suggested a role in the lateral gating mechanism 
for entry of TMD substrates into the complex. Interestingly, Pen-2 also undergoes a 
conformational change in class 3 relative to class 1 and class 2, along with changes in 
PSEN1, consistent with strong evidence that interaction of Pen-2 with TMD4 of PSEN1 is 
essential for protease function.
The enzyme complex was also analyzed by cryo-EM in the presence of an inhibitor called 
DAPT {N-[N-(3,5-difluor-ophenacetyl)-L-alanyl]-S-phenylglycine tert-butyl ester}, resulting 
in a structure of a single class determined at 4.2 Å overall resolution, with no general 
unknown helical density surrounded by PSEN1 TMDs130 (Figure 7B). While many side 
chains were unresolved, backbone features were clearly seen. Previous studies provided 
evidence that this tripeptide-like compound binds proximal to the enzyme active site,131,132 
and indeed, a density attributed to the inhibitor was observed close to the catalytic 
aspartates. Parts of PSEN1 that had been unresolved in the apo structures now became 
clearly defined in the inhibitor-bound structure. These PSEN1 regions include TMD2 and its 
flanking loops L1 and L2 as well as the cytosolic sides of TMD3 and TMD6. Also resolved 
is part of large loop L6, which undergoes autoproteolysis during the maturation and 
activation of the γ-secretase complex. Specifically, the conserved hydrophobic region of L6 
(E277–Y288), which represents the C-terminal end of the PSEN1 NTF subunit, appears to 
contribute to the enzyme active site, along with the now resolved cytosolic region of TMD6 
(P263–Q276). The rest of L6, which is not conserved and comprises the N-terminus of the 
PSEN1 CTF, remains invisible. L1 is also relatively large and contains a conserved 
hydrophobic stretch. This loop dips in and out of the transmembrane region to interact with 
TMD2, TMD3, and TMD5.
Notably, the DAPT-bound structure shows a cavity bound by TMD2, TMD3, and TMD5–
TMD7130 (see arrow in Figure 7B). In the class 1 and class 2 reconstructions of the 
apoenzyme, this cavity is occupied by the unaccounted for rodlike density attributed to 
bound, co-purified cellular substrates. Lining this cavity are many sites of FAD-causing 
PSEN1 missense mutations. Taken together, the DAPT-bound structure of γ-secretase 
suggests this inhibitor induces PSEN1 into a conformation similar to what it assumes upon 
substrate binding. Thus, this compound apparently inhibits the protease by trapping this 
conformation and precluding substrate binding.
Two new reports from the Shi laboratory provide the first detailed structures of the γ-
secretase complex bound to APP and Notch substrates.94,95 Two modifications were needed 
to stably trap the substrate on the enzyme. The first was mutation of one of the active site 
aspartates to alanine, to prevent proteolysis of the bound substrate. The second was cysteine 
mutation of both the substrate and presenilin to allow disulfide cross-linking. The sites of 
Cys mutation were in the N-terminal extracellular region of the substrate and in L1 of 
PSEN1. Thus, the enzyme was catalytically inactive, and the substrate was covalently bound 
to the enzyme in a manner that increases the likelihood of artifacts. Nevertheless, the 
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resulting enzyme–substrate complexes, with a bound substrate structure determined at 2.7 
and 2.6 Å resolution for Notch-and APP-derived substrates, respectively, provide 
considerable insights into the nature of substrate recognition by γ-secretase that are 
consistent with previous studies, discussed earlier here, and extend these findings with 
specific substrates.
In both cases, the bound substrate is located in the cavity observed in the DAPT-bound 
complex and filled by the unaccounted for rodlike density in class 1 and class 2 structures of 
the apoenzyme (Figure 8). Substrate TMD assumes a helical conformation for the first 14 or 
15 residues beginning at the extracellular side, and this helical region is surrounded by 
TMD2, TMD3, and TMD5. The conserved hydrophobic region of L1 that dips into the 
transmembrane region also appears to approach the substrate TMD, although this part of L1 
was largely mutated to polyalanine, perhaps because this provided better cryo-EM images or 
better disulfide cross-linking between the substrate and enzyme. Examination of this region 
of L1 in the class 1 and class 2 apoenzyme structures, which ostensibly contain the bound 
unidentified substrate, appears to validate the idea that this part of L1 is directly involved in 
substrate binding. The structures of bound APP and Notch substrates differ from that of the 
co-purified generic substrate on the extracellular side. For the former, the substrate turns into 
the complex, as it is forced to do through disulfide cross-linking, while the latter kinks away 
from the complex. As the generic substrate is not artificially cross-linked, the conformation 
of the extracellular region may be closer to reality.
Toward the cytosolic side of Notch and APP substrate TMD, the helical conformation ends 
just before entry into the active site, becoming first partially unwound and then fully 
extended into a β-strand. The β-strand of the substrate interacts with an antiparallel β-strand 
in the cytosolic region of TMD7, which in turn interacts with a β-strand in the conserved 
hydrophobic region at the C-terminus of PSEN1 NTF (part of what had been L6 before 
autoproteolysis) (see the insets in Figure 8). The β-strand of substrate TMD also interacts on 
its other side with an extended region of TMD9. Thus, the helical region of substrate TMD 
interacts with the PSEN1 NTF subunit, the β-strand region of substrate TMD interacts with 
the PS1 CTF subunit, and the region of the substrate in between, in the process of being 
unwound, interacts with both PSEN1 NTF and CTF. The unwinding of the substrate TMD 
helix in the active site and extension into a β-strand is consistent with biochemical 
expectations, as the scissile amide bond is not accessible when the substrate is in a helical 
conformation. These findings are also consistent with what is known about interactions of 
the substrate with soluble proteases. Substrates are generally bound to the active site in an 
extended conformation, although exceptions exist.133
The new structures with a bound substrate also revealed that many hot spots for Alzheimer’s 
disease-causing mutations in PSEN1 (positions with two or more different amino acid 
mutations134) directly interact with the substrate, for example, those in TMD2, TMD3, and 
TMD5 that surround the helical region of substrate TMD (Figure 9). In the DAPT-bound 
structure, these residues line the cavity filled by the substrate in the new co-structures. Other 
mutations are found elsewhere in the PSEN1 structure and may exert their effects indirectly, 
through allosteric mechanisms. Whether these mutations would be expected to affect 
substrate binding, helix unwinding, proteolysis in general, or specific proteolytic events is 
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not clear solely on the basis of the structure of the inactive but otherwise wild-type enzyme 
with the cross-linked substrate. No Alzheimer’s disease presenilin mutation has yet been 
found to cause a complete loss of proteolytic function. The closest case is L435F in 
PSEN1.135 This leucine, part of the PAL motif, is found immediately proximal to both 
catalytic aspartates in the substrate–enzyme co-structure, in a way that makes it easy to 
envision that mutation to phenylalanine could disrupt the ability of these aspartates to work 
together to activate a water molecule. However, L435F PSEN1 shows a clear ability to 
produce Aβ43,136,137 and this specific Aβ peptide was found deposited in the post-mortem 
brains of two human carriers of this mutation.137 Such observations run counter to the 
presenilin loss-of-function hypothesis.138
UNANSWERED QUESTIONS
The new cryo-EM structures of the γ-secretase complex with bound Notch and APP 
substrates provide substantial insight into the nature of substrate recognition. In both cases, 
the substrate fills a cavity formed upon binding of DAPT, implying that DAPT inhibits the 
protease by trapping it in the conformation the protease otherwise assumes upon substrate 
binding. The co-structures of γ-secretase with substrate are also consistent with previous 
findings using chemical probes and mutagenesis, discussed above, with the bound substrate 
TMD in a helical conformation until unwinding and extension occur in the active site. The 
fascinating visualization of the details of bound substrate now raises important follow-up 
questions about substrate recognition and enzyme mechanism.
The first question is how γ-secretase activates water within the confines of the lipid bilayer 
for use in hydrolysis. So far, the catalytic aspartates have been not quite close enough or not 
resolved clearly enough to offer an answer. In the case of the new structures with the bound 
substrate, the active site has been disabled by mutation of one of the catalytic aspartates to 
alanine. Without both aspartates, coordination with a water molecule is not possible, and the 
bound substrates in the new structures are not poised to undergo proteolysis. The cross-
linking of the substrate to presenilin in the complex also increases the potential for artifacts, 
with substrate adjusting itself for interaction with the enzyme in ways compatible with the 
artificial covalent attachment. The means of trapping the substrate to the enzyme without 
cross-linking or inactivation of the protease are needed to gain a more physiological picture 
of substrate recognition and intramembrane proteolysis.
The presence of both bound substrates surrounded by presenilin raises a second critical 
question. How does the substrate gain access to the interior of presenilin? These substrate-
bound structures reveal neither the location of the docking site nor the path of lateral entry. 
Mobile TMD2 is likely part of the lateral gating mechanism, but this remains to be tested. 
Lateral gating of substrates into the active site of a rhomboid serine proteases was explored 
through extensive mutagenesis to identify point mutations that increase the level of 
proteolytic cleavage, by loosening the contact between rhomboid TMD2 and TMD5.139 
Double-cysteine mutagenesis in both TMD2 and TMD5 allowed control of gate closing and 
opening through oxidation and reduction, respectively. Similar approaches could be taken to 
determine the substrate lateral gating pathway for γ-secretase. Regardless of the specific 
pathway for lateral gating, however, large loop L1 would appear to hinder substrate progress. 
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This loop may swing upward toward the extracellular region to make way for substrate entry, 
followed by swinging back inward to clamp the substrate.
Unwinding of the substrate is apparently a critical step in preparing the scissile amide bond 
for attack by activated water. How this unwinding occurs is the third critical question 
regarding substrate recognition and processing. Perhaps a network of hydrogen bond donors 
and acceptors on presenilin work to disrupt the helical conformation of substrate TMD, 
replacing the intramolecular hydrogen bonding arrangement with intermolecular 
interactions. Backbone amide bond NH and C═O in PSEN1 would be good candidates, as 
these stabilize the extended conformation of the substrate in the active site. These regions of 
presenilin likely undergo major conformational changes themselves in the process of 
unwinding substrate TMD. The cytoplasmic side of TMD7 and the C-terminus of the 
PSEN1 NTF subunit are invisible in the absence of the substrate but become ordered and 
extended upon interacting with the extended region of the substrate.
A fourth major question is how γ-secretase carries out processive proteolysis after 
endoproteolytic cleavage. Some-how the substrate must be repositioned to trim the initially 
formed N-terminal cleavage product in intervals of three amino acids. The presence of three 
S′ pockets apparently dictates carboxypeptidase cleavage every three residues, but does the 
substrate reposition itself through random motions to refill these pockets? Or does the 
enzyme actively participate in further substrate unwinding? Doing so may involve opening 
up the presenilin subunit to carry out successive unwinding steps. Such conformational 
“breathing” may occur not only for the cytoplasmic side of TMD7 and the C-terminus of 
PSEN1 NTF but also for TMD2 and loop L1.
Beyond the mechanistic questions, there is also great interest in the implications of the new 
structures for the design of Alzheimer’s disease therapeutics. γ-Secretase inhibitors have 
failed in clinical trials for Alzheimer’s disease,140,141 in part due to a lack of selectivity for 
APP over Notch processing. Interference with proper Notch signaling results in immuno-
suppression, gastrointestinal toxicity, and skin lesions. The new structures could provide the 
basis for the computer-aided design of inhibitors that are selective for blocking APP 
proteolysis over Notch. While some inhibitors apparently have such selectivity (so-called 
“Notch-sparing” γ-secretase inhibitors), one such compound also displayed toxicities 
connected to Notch signaling deficiencies in clinical trials,141 suggesting that selectivity was 
not sufficient to decrease the level of Aβ production in the brain without inhibiting Notch 
signaling in the periphery. In any event, the clinical failures of γ-secretase inhibitors are not 
only due to blocking Notch processing and signaling. Cognitive function actually worsened 
in Alzheimer’s disease subjects treated with inhibitors in these trials. Evidence from animal 
models suggests that cognitive worsening may be due to blocking of APP proteolysis and 
the resulting increase in levels of the APP-derived membrane-bound substrates.142
Rather than inhibition, modulation of γ-secretase activity would be preferred for the 
potential treatment of Alzheimer’s disease. Specifically, the goal would be to stimulate the 
carboxypeptidase trimming of long Aβ peptides to shorter versions, as this particular 
proteolytic function of γ-secretase is decreased in PSEN1 Alzheimer’s disease mutant γ-
secretase complexes.86,87,143,144 Such modulators would neither increase substrate levels nor 
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block processing of Notch and other critical γ-secretase substrates. Interestingly, such 
modulators were first identified in 2001 as agents that lower Aβ42 levels while increasing 
Aβ38 levels.145 It is now clear that these compounds specifically stimulate the γ-secretase-
mediated trimming of Aβ42 to Aβ38,86 and potent next-generation modulators are 
apparently advancing into clinical trials.146–148 The success of such agents, however, 
depends on Aβ42 being the trigger of Alzheimer’s disease pathogenesis and the ability to 
therapeutically intervene early enough. Neither of these critical issues has been resolved, 
emphasizing the need for more basic biomedical research before pushing through 
therapeutic candidates. Toward this end, the discovery of γ-secretase modulators that affect 
other specific Aβ trimming steps would offer valuable chemical tools for addressing critical 
questions about the molecular basis of Alzheimer’s disease. Such chemical tools may also 
be therapeutic prototypes that provide in vivo proof of principle and essential target 
validation. The new advances in understanding the structure and mechanism of γ-secretase 
should greatly facilitate the design and discovery of such new chemical tools and drug 
prototypes.
The γ-secretase complex is a central enzyme in biology and medicine, with the ability to 
carry out processive proteolysis in the membrane. As such, the enzyme continues to 
fascinate on many levels. Our collective understanding of the structure and mechanism of 
this membrane-embedded proteolytic machine has advanced dramatically in recent years 
with the application of cutting-edge cryo-EM technology. The consistency of the new 
detailed structures with findings using small-molecule probes and mutagenesis is gratifying 
and reassuring. Further work is essential to elucidate critical open questions regarding 
structure and mechanism, how Alzheimer’s disease-causing mutations alter structure and 
function, and how new understanding can be leveraged for drug discovery. The new 
structures provide a solid platform for future advances on all of these important fronts.
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Intramembrane proteolysis by the γ-secretase complex. γ-Secretase cleaves >90 different 
type I integral membrane proteins after ectodomain release by membrane-tethered 
sheddases. The protease complex carries out proteolysis in the transmembrane domain of 
these substrates to secrete N-terminal cleavage products into the extracellular milieu and 
release C-terminal cleavage products into the cytoplasm. The γ-secretase complex is 
composed of four different multipass membrane proteins, with presenilin as the catalytic 
component containing two transmembrane aspartates in the active site. Upon assembly with 
the other subunits (nicastrin, Aph-1, and Pen-2), presenilin undergoes autoproteolysis into an 
N-terminal fragment (NTF) and C-terminal fragment (CTF) to form active γ-secretase.
Wolfe Page 24














Processive proteolysis by γ-secretase. The protease first carries out endoproteolysis (ε) near 
the cytosolic end of the TMD of the APP substrate, with release of the intracellular domain 
(AICD). This is followed by carboxypeptidase cleavages (ζ, γ, and γ′) of the remaining 
long Aβ peptides, in intervals of roughly three amino acids, to secreted peptides that are 38–
43 residues in length. There are two general pathways for Aβ generation: Aβ49 → Aβ46 → 
Aβ43 → Aβ40 and Aβ48 → Aβ45 → Aβ42 → Aβ38.
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General mechanism of substrate recognition and processing by γ-secretase. Helical substrate 
TMD initially binds to presenilin at a docking exosite (where the helix is bound in ES1). 
This is followed by movement of the substrate in whole or in part (as shown) into the active 
site, with unwinding of the substrate TMD to set up the transition state (ES1*) for ε 
cleavage. After release of the intracellular domain, the remaining enzyme-bound product 
(ES2) again unwinds into the active site for carboxypeptidase cleavage (ES2*). Three 
pockets in the enzyme active site dictate trimming every three amino acids. Successive 
carboxypeptidase trimming occurs until short peptide products are released. The inset shows 
pockets S1′ and S3′ are relatively large and can accommodate bulky aromatic amino acids 
such as Phe, while S2′ is smaller and cannot accommodate Phe.
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Assembly and activation of the γ-secretase complex. Nicastrin and Aph-1 form a stable 
subcomplex (step 1), followed by addition of presenilin (step 2). Interaction of Pen-2 with 
TMD4 of presenilin (step 3) triggers autoproteolysis of presenilin into NTF and CTF 
subunits (step 4) to form γ-secretase capable of cleaving substrates.
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First detailed structure of the γ-secretase complex determined by cryo-EM, single-particle 
analysis, and image reconstruction, with the revised assignment of the presenilin TMDs: 
green for nicastrin, yellow for Aph-1, magenta for Pen-2, cyan (NTF) and aquamarine (CTF) 
for PS1, TMDs numbered, and red for catalytic aspartates. TMD2 was not resolved but was 
modeled using the crystal structure of an archaeal presenilin homologue. This TMD (“2”) is 
depicted as the dashed outlined cylinder. Looking only at the 19 TMDs of the complex from 
the cytosolic side (right) illustrates the horseshoe-shaped arrangement, with the active site 
that can be approached by the substrate from the convex side and flexible TMD2 as the 
apparent gate. Protein Data Bank entry 5A63.
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Nicastrin serves as a gatekeeper of the γ-secretase complex. The large ectodomain of 
nicastrin juts out over the entryway to the active site, sterically preventing access of 
substrates with ectodomains that are >20 Å long. Conformationally flexible TMD2 of 
presenilin is believed to be the gate, allowing substrate entry within the membrane. Protein 
Data Bank entry 5A63.
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Structures of γ-secretase determined using image classification and masked refinement. (A) 
Class 1 structure of the apoenzyme, with resolution of TMD2 of presenilin and the presence 
of an unidentified helical density (orange) in presenilin, thought to be a composite of 
multiple substrates co-purified with the protease complex. This density appears to unwind 
and disappear as it approaches the active site (catalytic aspartates colored red). TMDs of 
presenilin are numbered, and loop 1 (L1) is indicated. Protein Data Bank entry 5FN3. (B) 
Structure of the enzyme bound to small peptide inhibitor DAPT. The protease complex 
assumes a conformation similar to the class 1 structure but without the unidentified density. 
A cavity formed where this density would be is indicated by the large purple arrow. Other 
parts of presenilin become visible or rearrange, most notably the cytoplasmic side of TMD6, 
which becomes kinked and extended. DAPT, which was only partly resolved binding near 
the active site, is not shown for the sake of clarity. Protein Data Bank entry 5FN2.
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Structures of γ-secretase bound to substrates. (A) γ-Secretase bound to Notch1-derived 
substrate. Protein Data Bank entry 6IDF. (B) γ-Secretase bound to the APP-derived 
substrate. Protein Data Bank entry 6IYC. In both structures, the substrate is located inside 
PSEN1 with the same basic arrangement as that seen in the class 1 apoenzyme with the 
unidentified density (Figure 7A). Both substrates are now resolved as they unwind and enter 
the catalytically disabled active site (PSEN1 TMD7 Asp mutated to Ala). Insets show the 
substrate TMD assumes a β-strand conformation near the cytoplasmic side, stabilized by a 
β-strand in PSEN1 TMD7, which is in turn stabilized by a short β-strand at the C-terminus 
of PSEN1 NTF.
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Familial Alzheimer’s disease (FAD) hot spots in PSEN1. (A) Sixty-one residues that are 
each mutated to two or more different amino acids in FAD are colored purple. Only PSEN1 
and the APP substrate are shown for the sake of clarity. Note that many of these mutation 
sites appear to face or interact with the substrate. (B) Mutation sites that interact with the 
helical region of the substrate. (C) Mutation sites that interact, directly or indirectly, with the 
substrate in the active site and with the substrate β-strand. Protein Data Bank entry 6IYC.
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